What is Major Depressive Disorder?
Major Depressive Disorder (MDD) is a serious,
biologically-based disorder:
It is prevalent and debilitating, and can be chronic and life-threatening —in fact, it is the leading cause of suicide in the United States.
MDD is characterized by:
- Having a depressed mood or a loss of interest or pleasure in your daily activities consistently for at least a two-week period
- The symptoms impair your functioning at work or school, your social life, or other important areas
MDD is common and disabling:
- In 2019, 19.4 million adults in the U.S. had at least one major depressive episode
- Worldwide, depression is the #1 contributor to disability
unmet needs
- For the past 60 years, oral antidepressants have generally taken a similar approach to treating depression
- There is a need for new treatments that have a faster onset of action and higher remission rates, as well as being well-tolerated
-
- Current antidepressants commonly take weeks to months to achieve their full effect
- Many patients still have residual symptoms, and remission rates are low
- Side effects associated with current antidepressants include: sexual dysfunction, sleep disturbances, weight gain, nausea, vomiting, diarrhea, and cognitive impairment
key facts
Results of the Sequenced Treatment Alternatives to Relieve Depression, or STAR*D trial, funded by the National Institute of Mental Health, indicated that:


Nearly two-thirds of diagnosed and treated patients did not achieve remission with first line therapy.
Nearly two-thirds of diagnosed and treated patients did not achieve remission with first line therapy.
The majority of these initial failures also fail second line treatment

19.4 million
19.4 million
adults in the U.S.
had at least one major depressive episode
in 2019
*Treatment=seeing or talking to a health professional or other professional or using prescription medication for depression in the past year
†Based on the STAR*D study which included patients with major depressive disorder who received one (N=3,671) to four (N=123) successive acute treatment steps.
Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. The first-level treatment was an antidepressant.
The primary endpoint was remission defined as QIDS-SR16 score ≤5 at exit from the indicated treatment step.